Is Evolus, Inc. (EOLS) a Buy, Sell, or Hold?
NASDAQ : EOLS
Evolus, Inc.
$7.59 USD
$0.18 (2.43%)
- Volume
- 1.63M
- Average Volume
- 829.22K
- Market Capitalization
- $499.84M
- P/E Ratio
- -14.65
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $7.95
- Year Low
- $3.86
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.70
Company Overview
NASDAQ
David Moatazedi
Drug Manufacturers - Specialty & Generic
Healthcare
EOLS
334
US
USD
Liquidity Metrics
-5.33
1.70
1.28
0.46
0.00
Sales & Valuation
$297.18M
1.58
-16.19
-15.71
-0.48
Profitability
-$0.8
-$51.64M
-10.85%
-10.64%
123.11%
-13.84%
P/E Metrics
-14.65
-0.21
-0.21
Analyst Price Target & Rating
$17.00
$27.00
$13.00
2/5
13 Analysts
-55.35%
Financial Health Scores
-1.41
3/9
$68.81M
$248.02M
$278.93M
-$17.46M
Key Metrics (TTM)
$619.47M
1.96
-60.55
1.70
123.11%
-15.27%
-6.86%
-6.36%
60 days
Company Executives
| Name | Title |
|---|---|
| David Moatazedi | President, Chief Executive Officer & Director |
| Tatjana Mitchell | Chief Financial Officer |
| Nareg Sagherian | Head of Global Investor Relations & Corporate Communications |
| Kurt Knab | Senior Vice President of Sales |
| Jeffrey J. Plumer | Corporate Secretary |
| Rui Avelar C.CFP Dip.SportMed | Chief Medical Officer and Head of Research & Development |
| Jessica Novak | Senior Vice President of Human Resources |
Poll Results
No votes yet today — be the first to share your view!
About Evolus, Inc. (NASDAQ:EOLS) Stock
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California. ...
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
2026-08-06 00:30:02
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
2026-08-05 21:37:24
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.24 per share a year ago.
Evolus Q2 Earnings Call Highlights
2026-08-05 21:04:20
Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.
2026-08-05 16:05:00
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. “The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau® and accelerating adoption of Evolysse®,” said.
2026-08-04 09:00:00
[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announce
2026-08-04 08:30:00
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies' existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced “esteem”) collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zea.
Evolus to Report Second Quarter Financial Results on August 5, 2026
2026-07-22 08:30:00
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.To pa.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 16:05:00
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company's common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentiv.
Frequently Asked Questions
-
What is the current Evolus, Inc. (EOLS) stock price?
-
Evolus, Inc.(NASDAQ:EOLS) stock price is $7.59 in the last trading session. During the trading session, EOLS stock reached the peak price of $7.95 while $3.86 was the lowest point it dropped to. The percentage change in EOLS stock occurred in the recent session was 2.43% while the dollar amount for the price change in EOLS stock was $0.18.
-
EOLS's industry and sector of operation?
-
The NASDAQ listed EOLS is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of EOLS?
-
David Moatazedi | President, Chief Executive Officer & Director
Tatjana Mitchell | Chief Financial Officer
Nareg Sagherian | Head of Global Investor Relations & Corporate Communications
Kurt Knab | Senior Vice President of Sales
Jeffrey J. Plumer | Corporate Secretary -
How many employees does EOLS have?
-
Number of EOLS employees currently stands at 334. EOLS operates from 520 Newport Center Drive, Newport Beach, CA 92660, US.
-
Link for EOLS official website?
-
Official Website of EOLS is: https://www.evolus.com
-
How do I contact EOLS?
-
EOLS could be contacted at phone #949 284 4555 and can also be accessed through its website. EOLS operates from 520 Newport Center Drive, Newport Beach, CA 92660, US.
-
How many shares of EOLS are traded daily?
-
The average number of EOLS shares traded daily for last 3 months was 829.22K.
-
What is the market cap of EOLS currently?
-
The market value of EOLS currently stands at $499.84M with its latest stock price at $7.59